Calendar Year Performance 2015Calendar Year Performance 2016Calendar Year Performance 2017Calendar Year Performance 2018Calendar Year Performance 2019Calendar Year Performance 2020Calendar Year Performance 2021Calendar Year Performance 2022Calendar Year Performance 2023Calendar Year Performance 2024
- 1.4 %
+ 5.1 %
+ 10.4 %
- 9.6 %
+ 34.8 %
+ 14.5 %
+ 21.7 %
- 21.1 %
+ 14.8 %
+ 11.3 %
Net Asset Value
349.57 €
Asset Under Management
810 M €
Market
European market
SFDR - Fund Classification
Article
9
Data as of: 31 Dec 2024.
Data as of: 9 Jan 2025.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged. The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to https://eur-lex.europa.eu/eli/reg/2019/2088/oj.Until 31 December 2024, the Fund's reference indicator is Stoxx Europe 600 NR index. Performances are presented using the chaining method.
In December, Europe traded down around 0.5% for the month, with most of this decline occurring towards the end due to a hawkish Fed outlook for 2025, which impacted markets.
Europe’s largest company, Novo Nordisk, also disappointed the market towards the end of the month, further affecting the wider market.
The optimism generated in November by Trump's victory in the US elections has faded, with investors turning their attention to the impact of possible US tariffs and to the question of whether the Franco-German motor of the European Union will stall.
Performance commentary
During the month of December, the Fund recorded a slightly negative absolute performance, above its reference indicator.
Hermes has been the fund's top performer this month, driven by sell-side analysts' positive outlook on its resilient business model and high brand desirability.
Galderma, a recent addition to our portfolio, has also contributed to the Fund's performance. The company is poised to benefit from the early success of its newly approved atopic dermatitis treatment in the US.
Our biggest detractors this month has been Novo Nordisk whose shares experienced a significant decline on December 20th following disappointing results from tests of its latest obesity drug, CagriSema.
Despite this setback, CagriSema remains a valuable addition to Novo Nordisk's obesity product range and competes directly with Eli Lilly’s Zepbound
Having no exposure to Communication Services and Energy sectors has been supportive during the month.
Outlook strategy
During the month, our portfolio remained relatively stable without any major changes.
We decided to take some profits in a few names that have performed well recently, particularly our Financials holdings such as Euronext and Deutsche Borse.
On the other hand, we took advantage of the significant drop to increase our position in Novo Nordisk as our conviction didn’t significantly change.
The Fund continues to rely on bottom-up fundamental analysis with a medium-long term horizon.
We stick to our process of focusing on profitable companies with high returns on capital, reinvesting for growth and maintain our focus on stocks and sectors with strong visibility on sales and profits.
Until 31 December 2024, the Fund's reference indicator is Stoxx Europe 600 NR index. Performances are presented using the chaining method.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
Carmignac Portfolio is a sub-fund of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor), where applicable. Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.). The reference to a ranking or prize, is no guarantee of the future results of the UCITS or the manager.
Unsupported browserWe've noticed that your browser is no longer supported. To ensure optimal performance and security while using our website, we recommend updating your browser or other relevant software. Thank you for your understanding!
Market environment